We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
13.00 | 1.35% | 977.40 | 976.80 | 977.20 | 979.20 | 965.00 | 965.00 | 867,577 | 11:43:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Ortho,prosth,surg Appl,suply | 5.55B | 263M | 0.3011 | 32.40 | 8.52B |
Date | Subject | Author | Discuss |
---|---|---|---|
14/11/2011 10:03 | $4bn turnover and profits varying between $400-600mn. 'Tis a sitting duck and about ruffle a few feathers IMHO. ArtN | artnouveau | |
14/11/2011 10:00 | A sitting duck imo. | philo124 | |
14/11/2011 09:57 | Keeps spiking up on Friday and today. Quality in an unstable market or are those bid rumours back up and running? ArtN | artnouveau | |
09/11/2011 13:43 | anyone else think it's going to be a big challenge to switch their major manufacturing operation to lower cost countries - all while maintaining their excellent quality and service?. Its what I do and I can tell you that while all the consultants say it can be done its a nightmare. M | magli | |
07/11/2011 15:34 | Suprised by the lack of discussion here on the update. Anyone else think it's going to be a big challenge to switch their major manufacturing operation to lower cost countries - all while maintaining their excellent quality and service?. | essentialinvestor | |
04/11/2011 09:48 | Agree again, the balance sheet is lean and S&N could be the hunter and not the hunted. ArtN | artnouveau | |
04/11/2011 09:42 | Fair enough Art, however remember that SN. may be the buyer rather than a target, and that could mean a major rights issue. Two sides of the coin - hopefully the CEO would not be tempted into a major acquisition. The margin decline in such a short period of time is hugely disappointing imv. | essentialinvestor | |
04/11/2011 09:34 | I don't disagree with your view EI but there's synergies to be had in a competitive market and as we all know M&A activity will accelerate next year. I wouldn't mind betting the likes of Smith & Nephew, Cobham and Lonmin aren't involved. S&N's low debt will also attract private equity let alone any other suitors... ArtN | artnouveau | |
04/11/2011 09:27 | I listened to the last webcast with the CEO a couple of times, and he stressed that the strategic review was not necessarily about cost cutting, just more focussed working practices ... within just a few weeks of that interview we have this mornings statement. What guarantee is there that margins will improve so dramatically in Q4?, as just a few weeks ago that decline was not anticipated. I also have some doubts that SN. will be able to maintain anything like current margins in emerging economies where they want to grow. Too much opticism here, all imv, dyor as always. | essentialinvestor | |
04/11/2011 09:16 | Major regulatory hurdles to any bid and J&J went elsewhere, having just completed a huge acquisition. The recent weakness in the share price has been borne out by today's results imv. | essentialinvestor | |
04/11/2011 08:56 | revenue up but margin pressure explains why the city are marking them down a bit. Yet they remain a quality growth play and the m&a chance remains. I think the city could do with another deal after losing £40m+ of fees on the aborted g4s deal last week! | edwardt | |
04/11/2011 08:16 | Certainly a possible bid situation here, S&N's debt down to below $100mn from $600mn. Looks a quality sitting duck to me. No doubt Biomet and Stryker will be mentioned again. ArtN | artnouveau | |
04/11/2011 08:08 | I don't think so; the chances of a bid at 700p being made & accepted have increased imo. | philo124 | |
04/11/2011 07:30 | Has to be said, stonking Q3 results... | artnouveau | |
02/11/2011 08:58 | The Stryker share price fell heavily yesterday. SN. looks good longer term value to me, however the yeild is not supportive when so many are looking for income. | essentialinvestor | |
20/10/2011 09:43 | good read across from the strycker results last night in the staes, should be supportive for shares.. | edwardt | |
31/8/2011 08:34 | CS have a valuation of 900p. | philo124 | |
31/8/2011 08:31 | looks like stryker bid rumours are doing the rounds again, hence strong share price | edwardt | |
05/8/2011 20:29 | hmm..maybe 500 | badtime | |
04/8/2011 20:29 | Hmmm might b tempted at 550 | badtime | |
03/8/2011 19:35 | BELOW £6, TOTALLY IRRATIONAL. | philo124 | |
11/5/2011 13:45 | Smith & Nephew upgraded to buy from reduce at Kepler, TP 760p vs 750p. | nellie1973 | |
05/5/2011 18:49 | Yep, in SIPP , no hurry. | philo124 | |
05/5/2011 15:50 | Yeah, 1st quarter results out earlier as well. Quite a steady share this one with a chance of a bid but very good growth prospects too. One to tuck away and keep in the SIPP with the likes of SOCO & M&S me feels. ArtN | artnouveau |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions